RefleXion Secures Expanded Medicare Payment for SCINTIX Cancer Therapy

Got story updates? Submit your updates here. ›

RefleXion Medical, a leading provider of advanced cancer therapies, has announced that it has secured expanded Medicare coverage for its SCINTIX cancer treatment. This new payment policy from the Centers for Medicare & Medicaid Services (CMS) will significantly increase access to this innovative radiation therapy for Medicare beneficiaries across the United States.

Why it matters

The expanded Medicare coverage for SCINTIX is an important milestone that will make this advanced cancer treatment more accessible to a wider population of patients. SCINTIX uses real-time tumor tracking and precision radiation delivery to target tumors while minimizing damage to surrounding healthy tissue, offering an effective and less invasive alternative to traditional radiation therapy.

The details

SCINTIX is RefleXion's pioneering biology-guided radiotherapy system that combines positron emission tomography (PET) imaging with stereotactic body radiotherapy (SBRT) to precisely target tumors. The new CMS policy will provide national Medicare coverage for SCINTIX treatments, enabling more cancer patients to benefit from this innovative approach.

• The new Medicare coverage policy for SCINTIX took effect on April 1, 2026.

What they’re saying

What’s next

The expanded Medicare coverage for SCINTIX is expected to increase adoption of this innovative cancer treatment among healthcare providers and improve outcomes for Medicare patients with a variety of solid tumor types.